Journal articles: 'Lu-177'

1

Wiwanitkit, Viroj. "(177)Lu-nimotuzumab." Nuclear Medicine and Biology 39, no. 6 (August 2012): 891. http://dx.doi.org/10.1016/j.nucmedbio.2012.01.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Rousseau, Etienne, Joseph Lau, Zhengxing Zhang, Chengcheng Zhang, Daniel Kwon, Carlos F. Uribe, Hsiou-Ting Kuo, et al. "Comparison of biological properties of [177 Lu]Lu-ProBOMB1 and [177 Lu]Lu-NeoBOMB1 for GRPR targeting." Journal of Labelled Compounds and Radiopharmaceuticals 63, no. 2 (January 11, 2020): 56–64. http://dx.doi.org/10.1002/jlcr.3815.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Meléndez‐Alafort, Laura, Guillermina Ferro‐Flores, Clara Santos‐Cuevas, Blanca Ocampo‐García, Sofia Turato, Giulio Fracasso, Cristina Bolzati, Antonio Rosato, and Laura De Nardo. "Preclinical dosimetric studies of 177 Lu‐scFvD2B and comparison with 177 Lu‐PSMA‐617 and 177 Lu‐iPSMA endoradiotherapeutic agents." Medical Physics 48, no. 7 (June 7, 2021): 4064–74. http://dx.doi.org/10.1002/mp.14936.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Zolghadri, Samaneh, Hassan Yousefnia, Amir Reza Jalilian, and Yousef Fazaeli. "Production, quality control, biodistribution assessment and preliminary dose evaluation of [177Lu]-tetra phenyl porphyrin complex as a possible therapeutic agent." Brazilian Journal of Pharmaceutical Sciences 51, no. 2 (June 2015): 339–48. http://dx.doi.org/10.1590/s1984-82502015000200011.

Full text

Abstract:

Due to interesting therapeutic properties of 177Lu and tumor avidity of tetraphenyl porphyrins (TPPs), 177Lu-tetraphenyl porphyrin was developed as a possible therapeutic compound. 177Lu of 2.6-3 GBq/mg specific activity was obtained by irradiation of natural Lu2O3sample with thermal neutron flux of 4 × 1013 n.cm-2.s-1. Tetraphenyl porphyrin was synthetized and labeled with 177Lu. Radiochemical purity of the complex was studied using Instant thin layer chromatography (ITLC) method. Stability of the complex was checked in final formulation and human serum for 48 h. The biodistribution of the labeled compound in vital organs of wild-type rats was studied up to 7 d. The absorbed dose of each human organ was calculated by medical internal radiation dose (MIRD) method. A detailed comparative pharmacokinetic study was performed for 177Lu cation and [177Lu]-TPP. The complex was prepared with a radiochemical purity: >97±1% and specific activity: 970-1000 MBq/mmol. Biodistribution data and dosimetric results showed that all tissues receive approximately an insignificant absorbed dose due to rapid excretion of the complex through the urinary tract. [177Lu]-TPP can be an interesting tumor targeting agent due to low liver uptake and very low absorbed dose of approximately 0.036 to the total body of human.

APA, Harvard, Vancouver, ISO, and other styles

5

&NA;. "Octreotate-Lu-177-DOTA-Tyr-3." Reactions Weekly &NA;, no. 1207 (June 2008): 26–27. http://dx.doi.org/10.2165/00128415-200812070-00078.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

&NA;. "Lu-177-octreotide/yttrium-90-DOTATOC." Reactions Weekly &NA;, no. 1415 (August 2012): 32–33. http://dx.doi.org/10.2165/00128415-201214150-00116.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Park, Ul Jae, Jun-Sig Lee, Kang Hyuk Choi, Sung Soo Nam, and Kook Hyun Yu. "Lu-177 preparation for radiotherapy application." Applied Radiation and Isotopes 115 (September 2016): 8–12. http://dx.doi.org/10.1016/j.apradiso.2016.05.028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Stangl-Kremser, Judith, Sazan Rasul, Jeffrey J. Tosoian, Simpa Salami, Alexander Zaslavsky, Aaron M. Udager, Peter Mazal, et al. "Single-lesion PSMA protein expression and response to Lu-177 PSMA therapy in patients with castration-resistant prostate cancer." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 5065. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.5065.

Full text

Abstract:

5065 Background: The recent introduction of Lu-177 PSMA for the treatment of castration-resistant prostate cancer (CRPC) has been met with much excitement. Initial reports of clinical response are promising, despite known inter- and intra-patient molecular heterogeneity. In this study, we examined the utility of PSMA protein expression in metastatic tumor tissues as a predictor of lesion-specific response to Lu-177 PSMA therapy in men with CRPC. Methods: Between 2015-2020, 19 patients with metastases at multiple sites underwent metastatic lesion biopsy, Ga-68 PSMA PET imaging, and subsequent treatment with three cycles of Lu-177 PSMA. A monoclonal anti-PSMA antibody (EPITOMICS (USA), 1:50) was used to semi-quantitatively assess PSMA protein expression in the biopsy specimen. The histoscore (range 0-300) was derived from intensity and extent of the immunohistochemistry staining and was determined by experienced genitourinary pathologists. Imaging evaluation was performed according to the Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) criteria. We assessed the association of the PSMA protein expression in metastatic tumor tissues and the lesion-specific response to Lu-177 PSMA therapy. Results: In 12 patients with biopsy specimens available for staining, PSMA expression correlated with enhancement (SUVmax) of the biopsy site on Ga-68 PSMA PET imaging (rs = 0.63). Of the nine patients with repeat imaging after Lu-177 PSMA therapy, five (55.6%) had a lesion-specific response at the site of biopsy. PSMA expression on immunohistochemistry was unable to accurately predict lesion-specific response in univariable analysis (p = 0.81, 95% CI 94.6-76.6). Among the five men with a lesion-specific response, three (60%) experienced overall progression based on PERCIST. There was no association between lesion-specific response and overall progression (p = 0.64). Conclusions: In patients with multiple metastases, PSMA protein expression from a single site biopsy was not predictive of site-specific Lu-177 PSMA response based on PERCIST. Additional studies are necessary to further interrogate the clinical consequence of PSMA expression heterogeneity in metastatic sites as well as the mechanisms underpinning resistance to Lu-177 PSMA in patients with CRPC.

APA, Harvard, Vancouver, ISO, and other styles

9

Gosewisch, Astrid, Harun Ilhan, Lena Vomacka, and Guido Böning. "Dosimetrie bei der Radionuklidtherapie mit Lu-177." Der Nuklearmediziner 41, no. 01 (March 2018): 69–80. http://dx.doi.org/10.1055/s-0043-122171.

Full text

Abstract:

ZusammenfassungDie Radioligandentherapie (RLT) mit radioaktiv markierten PSMA-Liganden (z. B. Lu-177-PSMA-617) und die Peptid-Rezeptor-Radionuklidtherapie (PRRT) mit radioaktiv markierten Somatostatin-Analoga (z. B. Lu-177-DOTATATE) haben sich über die letzten Jahre als vielversprechende Therapieoptionen bei metastasierten, kastrationsresistenten Prostatakarzinomen bzw. inoperablen oder metastasierten neuroendokrinen Tumoren entwickelt. Das Theragnostiknuklid Lu-177 weist dabei neben der Therapie-relevanten Beta-Minus-Komponente eine, auch für die Bildgebung gut nutzbare, Gammaemission auf, die eine direkte quantitative Bildgebung und Dosimetrie der Radiopharmakonverteilung möglich macht. Die Patienten-spezifische 3D-Dosimetrie auf Basis der quantitativen Lu-177-Bildgebung ist dabei der Schlüssel hin zur individualisierten Therapiekontrolle und -planung in der RLT und PRRT, in denen bisher vornehmlich noch standardisierte Aktivitätsmengen verabreicht werden. Jedoch ist die Ermittlung robuster Dosiswerte klinisch aufwändig, sowohl bez. des Messaufwands als auch hinsichtlich der Auswertung der Daten, und die starke Variabilität der Dosiswerte und deren Abhängigkeit von der verwendeten Methodik erschweren die Etablierung Therapie-spezifischer Dosis-Wirkungsbeziehungen. Gerade der Vergleich von Dosimetriedaten zwischen den Kliniken erfordert eine systematische und vereinheitlichte Dosimetrie mit akzeptablem klinischem Aufwand. Die Genauigkeit der Dosimetrie ist derzeit v. a. limitiert durch Effekte der Bildgebung. Zusätzliche Fehler können sich bspw. durch eine ungünstige Wahl der gemessenen Datenpunkte, Bewegungsartefakte, Überlagerungseffekte in der planaren Bildgebung oder durch eine nicht vollständig klinisch durchführbare Definition der Zielregion (z. B. Knochenmark) ergeben. Die 3D-Dosimetrie, unter Berücksichtigung zusätzlicher physikalischer oder biologischer Parameter (z. B. Dosisrate), kann in der Radionuklidtherapie einen wichtigen Beitrag zur Etablierung von Dosis-Wirkungsbeziehungen liefern, allerdings ist die klinisch-physiologische Interpretation der 3D-Dosisverteilungen derzeit noch stark limitiert durch Bildartefakte und Bildrauschen in den zur Dosimetrie eingesetzten SPECT-Bildern.

APA, Harvard, Vancouver, ISO, and other styles

10

Snyder, W., K. Harpool, J. W. Swanson, P. Schantz, A. Phan, J. S. Dick, and S. X. Cavanaugh. "Establishing a Lu-177 Dotatate Therapy Program." International Journal of Radiation Oncology*Biology*Physics 102, no. 3 (November 2018): e499-e500. http://dx.doi.org/10.1016/j.ijrobp.2018.07.1419.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Zhang, Guoqiang, Zhizhong Sun, Hongtao Song, Mingming Zhen, Mirong Guan, Taiwei Chu, Shunzhong Luo, Chunru Wang, and Chunying Shu. "Radioactive lutetium metallofullerene 177LuxLu(3−x)N@C80–PCBPEG derivative: a potential tumor-targeted theranostic agent." Journal of Materials Chemistry B 3, no. 35 (2015): 7011–13. http://dx.doi.org/10.1039/c5tb00983a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Liu, Z., K. S. Schaap, L. Ballemans, R. de Zanger, E. de Blois, M. Rohde, and E. Oehlke. "Measurement of reaction kinetics of [177Lu]Lu-DOTA-TATE using a microfluidic system." Dalton Transactions 46, no. 42 (2017): 14669–76. http://dx.doi.org/10.1039/c7dt01830d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Graf, Josephine, Ulrich-Frank Pape, Henning Jann, Timm Denecke, Ruza Arsenic, Winfried Brenner, Marianne Pavel, and Vikas Prasad. "Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE." European Journal of Nuclear Medicine and Molecular Imaging 47, no. 4 (August 14, 2019): 881–94. http://dx.doi.org/10.1007/s00259-019-04439-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Lassmann, Michael, and Uta Eberlein. "Radiation Dosimetry Aspects of ¹⁷⁷Lu." Current Radiopharmaceuticals 8, no. 2 (August 19, 2015): 139–44. http://dx.doi.org/10.2174/1874471008666150313104212.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Желтоножский, В. А., М. В. Желтоножская, А. В. Саврасов, С. С. Белышев, А. П. Черняев, and В. Н. Яценко. "Исследование активации 177 Lu в (γ, рxn )-реакциях." Известия Российской академии наук. Серия физическая 84, no. 8 (2020): 1116–21. http://dx.doi.org/10.31857/s0367676520080347.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Fendler, Wolfgang P., Kambiz Rahbar, Ken Herrmann, Clemens Kratochwil, and Matthias Eiber. "177 Lu-PSMA Radioligand Therapy for Prostate Cancer." Journal of Nuclear Medicine 58, no. 8 (June 29, 2017): 1196–200. http://dx.doi.org/10.2967/jnumed.117.191023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Ak Sivrikoz, İlknur, Gülin Uçmak, Gamze Kaya Çapa, Emre Demirci, Nalan Alan Selçuk, Cüneyt Türkmen, Umut Elboğa, and Levent Kabasakal. "Procedure Guidelines for Lu-177 PSMA Radyoligand Treatment." Nuclear Medicine Seminars 6, no. 3 (December 24, 2020): 385–96. http://dx.doi.org/10.4274/nts.galenos.2020.0031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Дьячков, А. Б., А. А. Горкунов, А. В. Лабозин, С. М. Миронов, Г. О. Цветков, В. Я. Панченко, and В. А. Фирсов. "Исследование схемы селективной фотоионизации -=SUP=-177-=/SUP=-Lu." Журнал технической физики 126, no. 2 (2019): 103. http://dx.doi.org/10.21883/os.2019.02.47189.212-18.

Full text

Abstract:

AbstractThe hyperfine structure of transitions in the three-step scheme 5 d 6 s ^22 D _3/2–5 d 6 s 6 p ^4 F $$_{{5/2}}^{^\circ }$$ –5 d 6 s 7 s ^4 D _3/2– (53 375 cm^–1) $$_{{1/2}}^{^\circ }$$ of lutetium ionization is studied for ^175Lu, ^176Lu, and ^177Lu isotopes using the photoionization laser spectroscopy method. Values of the magnetic dipole ( A ) and electric quadrupole ( B ) interaction constants are determined, as well as the energies, the isotope shifts, and the radiative lifetimes for the 5 d 6 s 7 s ^4 D _3/2 and (53 375 cm^–1) $$_{{1/2}}^{^\circ }$$ levels.

APA, Harvard, Vancouver, ISO, and other styles

19

Polyak, Andras, Lívia Naszályi Nagy, Eszter Drotár, Gabriella Dabasi, Róbert P. Jóba, Zita Pöstényi, Renata Mikolajczak, Attila Bóta, and Lajos Balogh. "Lu-177-Labeled Zirconia Particles for Radiation Synovectomy." Cancer Biotherapy and Radiopharmaceuticals 30, no. 10 (December 2015): 433–38. http://dx.doi.org/10.1089/cbr.2015.1881.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Lin, Frank, Jaydira Del Rivero, Jorge A. Carrasquillo, Abhishek Jha, Melissa K. Gonzales, Liza Lindenberg, Baris Turkbey, et al. "Phase 2 trial of Lu-177-DOTATATE in inoperable pheochromocytoma/paraganglioma." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): TPS4159. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.tps4159.

Full text

Abstract:

TPS4159 Background: Pheochromocytoma/paraganglioma (PHEO/PGL) is a rare malignancy that arises from chromaffin cells of typically the adrenal medulla but can also be of extra-adrenal origin. These tumors produce excessive catecholamines such as epinephrine and norepinephrine which causes labile hypertension, tachycardia, and flushing. Lu-177-DOTATATE (Lu-177-dodecanetetraacetic acid‐tyrosine-3-octreotate) is a radiolabeled somatostatin analog that is FDA approved for somatostatin receptor-positive neuroendocrine tumors. It is being being investigated in PHEO/PGL, which overexpress somatostatin receptors. Amino acid solutions containing lysine/arginine (L/A) are routinely co-administered with Lu-177-DOTATATE for renal radioprotection, although solutions containing other amino acids are also used. Methods: This is a prospective, single center, open label Phase 2 study evaluating the efficacy of Lu-177-DOTATATE in PHEO/PGL. Ninety patients will be enrolled, divided into two cohorts of 45 patients each ( SDHx mutation vs. apparent sporadic). Lu-177-DOTATATE is given at a fixed dose of 200 mCi with a co-administration of L/A amino acid solution q8 weeks for 4 cycles. The primary endpoint is the progression-free-survival (PFS) rate at 6 months. Secondary endpoints include response rate, overall survival, time to progression, quality of life measures, and examination of potential biomarkers such as biochemical profiles, Ga-68-DOTATATE PET, and F-18-FDG PET scans. Eligibility criteria include inoperable disease (including non-metastatic), histological confirmation of PHEO/PGL, evidence of disease progression by RECIST 1.1, ECOG performance status of 1 or better, and a positive Ga-68-DOTATATE PET scan. Exclusion criteria include prior treatment with systemic radionuclide therapy such as I-131-MIBG, brain parenchymal metastases, and standard organ dysfunction limitations. Interim analysis using a Simon two-stage optimal design will be performed separately for each cohort after enrollment of 18 patients. First patient accrual to this ongoing study was in the Fall of 2017, and as of February 2019, fourteen patients have been accrued. Preliminary results will be reported at the completion of stage 1 for each cohort. Clinical trial information: NCT03206060.

APA, Harvard, Vancouver, ISO, and other styles

21

Alonzo, Nicholas, Magdalena Seyer, Eun-Jeong Kim, Rawmina Keshavarzi, Kathryn Yee, and Pamela L. Kunz. "Evaluation of the incidence of acute nausea and vomiting after administration of an amino acid solution containing only arginine and lysine with lutetium Lu-177 dotatate." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 12113. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.12113.

Full text

Abstract:

12113 Background: Lutetium Lu-177 dotatate is used to treat patients with gastroenteropancreatic neuroendocrine tumors, and an amino acid (AA) solution must be administered concurrently to mitigate nephrotoxicity. AA solutions may lead to increased rates of nausea and vomiting (NV) due to the inclusion of unnecessary non-essential and essential AA. Methods: This study is a single academic center retrospective chart review from October 6th, 2015 to December 17th, 2019 evaluating the incidence of acute NV in adult patients after administration of an AA solution containing only arginine 25 grams and lysine 25 grams in 1 liter of normal saline (Arginine-Lysine amino acid [AL AA]) with lutetium Lu-177 dotatate. The incidence of acute NV will be compared to the historical incidence in patients administered Parenteral amino acids 10%, Aminosyn II 10% or Clinisol 15% (commercial AA). Secondary endpoints include the incidence of rescue anti-emetic usage and the percentage of patients that require interruption of the AA infusion. Acute NV are defined as any occurrence of NV within twenty-four hours of the AA infusion. Results: 53 patients received a total of 164 treatments with the AL AA, while 18 patients received a total of 48 treatments with the commercial AA. The AL AA significantly decreased the incidence of acute NV, the mean AA infusion time, the interruption of the AA infusion, and the utilization of rescue anti-emetics compared to the commercial AA (Table) in patients on lutetium Lu-177 dotatate. Conclusions: The study findings support the use of an AL AA to be administered concurrently with lutetium Lu-177 dotatate to minimize commercial AA related acute NV. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

22

Chen, F., M. Turker, K. Ma, P. Zanzonico, F. Gallazzi, U. Wiesner, M. Bradbury, Th Quinn, and X. Zhang. "Lu-177 radiolabeled ultrasmall C’ dot nanoparticle melanoma theranostics." Nuclear Medicine and Biology 72-73 (July 2019): S60. http://dx.doi.org/10.1016/s0969-8051(19)30353-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

&NA;. "Octreotate-Lu-177-DOTA-Tyr-3/yttrium-90-DOTATOC." Reactions Weekly &NA;, no. 1401 (May 2012): 28–29. http://dx.doi.org/10.2165/00128415-201214010-00108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Bast, R., E. E. Scherer, P. Sprung, M. Fischer-Gödde, A. Stracke, and K. Mezger. "A rapid and efficient ion-exchange chromatography for Lu–Hf, Sm–Nd, and Rb–Sr geochronology and the routine isotope analysis of sub-ng amounts of Hf by MC-ICP-MS." Journal of Analytical Atomic Spectrometry 30, no. 11 (2015): 2323–33. http://dx.doi.org/10.1039/c5ja00283d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Satpati, Drishty, Ashis Satpati, Yugandhara Pamale, Chandan Kumar, Rohit Sharma, Haladhar Deb Sarma, and Sharmila Banerjee. "177Lu-labeled carbon nanospheres: a new entry in the field of targeted radionanomedicine." RSC Advances 6, no. 56 (2016): 50761–69. http://dx.doi.org/10.1039/c5ra25502c.

Full text

Abstract:

¹⁷⁷Lu-labeled carbon nanospheres loaded with cRGDfK peptide have been developed as radionanoprobes with favorable pharmacokinetics for integrin α_vβ₃-mediated active targeting.

APA, Harvard, Vancouver, ISO, and other styles

26

Hervás, I., P. Bello, M. Falgas, M. I. del Olmo, I. Torres, C. Olivas, V. Vera, P. Oliván, and A. M. Yepes. "177 Lu-DOTATATE treatment in neuroendocrine tumors. A preliminary study." Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 36, no. 2 (March 2017): 91–98. http://dx.doi.org/10.1016/j.remnie.2017.01.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Ponsard, B. "Production of Lu-177 in the BR2 high-flux reactor." Nuclear Medicine and Biology 41, no. 7 (August 2014): 648. http://dx.doi.org/10.1016/j.nucmedbio.2014.05.062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Said, MA, MA Masud, MZ Zaini, RA Salleh, BN Lee, and R. Zainon. "Lu-177 DOTATATE dosimetry for neuroendocrine tumor: single center experience." Journal of Physics: Conference Series 851 (May 2017): 012017. http://dx.doi.org/10.1088/1742-6596/851/1/012017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Zimmerman, B. E. "Report of the CCRI comparison CCRI(II)-K2.Lu-177." Metrologia 50, no. 1A (January 1, 2013): 06020. http://dx.doi.org/10.1088/0026-1394/50/1a/06020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Zhen-Hua, Zhang, Qi Shou-Tao, Sun Bao-Xi, Lei Yi-An, and Zeng Jin-Yan. "Particle-number-conserving analysis of multiquasiparticle bands in 177 Lu." Chinese Physics C 34, no. 1 (January 2010): 39–44. http://dx.doi.org/10.1088/1674-1137/34/1/007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Kamaleshwaran, KoramadaiKaruppusamy, Venkataraman Rajamani, SubbiahGounder Thirumalaisamy, Sudipta Chakraborty, Radhakrishnan Kalarikal, Vyshakh Mohanan, and AjitSugunan Shinto. "Radiosynovectomy of the elbow joint synovitis in rheumatoid arthritis treated with Lutetium - 177 labeled hydroxylapatite (Lu-177 HA) particulates; first case report and image of Lu -177 HA in the elbow joint." Indian Journal of Nuclear Medicine 29, no. 4 (2014): 270. http://dx.doi.org/10.4103/0972-3919.142644.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

van Kalmthout, Ludwike W. M., Esmée C. A. van der Sar, Arthur J. A. T. Braat, Bart de Keizer, and Marnix G. E. H. Lam. "Lutetium-177-PSMA therapy for prostate cancer patients—a brief overview of the literature." Tijdschrift voor Urologie 10, no. 6-7 (August 26, 2020): 141–46. http://dx.doi.org/10.1007/s13629-020-00300-z.

Full text

Abstract:

Abstract Radioligand therapy with lutetium-177 prostate specific membrane antigen ([177Lu]Lu-PSMA) represents a promising treatment for metastatic castration-resistant prostate cancer patients. In this paper, we aim to summarize the current knowledge derived from the literature as well as the authors’ experiences on [177Lu]Lu-PSMA therapy. Various systematic reviews, mostly including small retrospective studies, summarized efficacy and oncological outcomes of [177Lu]Lu-PSMA therapy. Any therapy-related prostate-specific antigen (PSA) response was reported in the majority of the patients (68–75%); >50% PSA decline was demonstrated in 34.5–51% of the patients. Incidence of side effects was low and in most patients, hematological toxicity remained limited to Common Terminology Criteria for Adverse Events (CTCAE) grade 1–2. Also, favorable efficacy was shown with regard to tumor response on imaging, pain symptoms and quality of life. In the near future, results of the awaited pivotal prospective studies (NCT03511664, NCT03392428) will define efficacy of [177Lu]Lu-PSMA therapy and its oncological value for metastatic castration-resistant prostate cancer patients.

APA, Harvard, Vancouver, ISO, and other styles

33

Konijnenberg, Mark. "Consequences of meta-stable ^177mLu admixture in ¹⁷⁷Lu for patient dosimetry." Current Radiopharmaceuticals 8, no. 2 (August 19, 2015): 145–49. http://dx.doi.org/10.2174/1874471008666150313121315.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Yordanova, Anna, Paula Linden, Stefan Hauser, Georg Feldmann, Peter Brossart, Rolf Fimmers, Markus Essler, Stefan Holdenrieder, and Hojjat Ahmadzadehfar. "The value of tumor markers in men with metastatic prostate cancer undergoing [ 177 Lu]Lu‐PSMA therapy." Prostate 80, no. 1 (October 3, 2019): 17–27. http://dx.doi.org/10.1002/pros.23912.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Boldyrev, P. P., A. V. Kurochkin, R. F. Nurtdinov, M. A. Proshin, D. Yu Chuvilin, and Yu A. Yashin. "Electrochemical method for producing radionuclide Lu-177 with high specific activity." Moscow University Chemistry Bulletin 71, no. 3 (May 2016): 193–98. http://dx.doi.org/10.3103/s0027131416030032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Parus, Józef, Dariusz Pawlak, Renata Mikolajczak, and Adriano Duatti. "Chemistry and bifunctional chelating agents for binding ¹⁷⁷Lu." Current Radiopharmaceuticals 8, no. 2 (August 19, 2015): 86–94. http://dx.doi.org/10.2174/1874471008666150312160440.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Novikov, S. G., A. V. Berintsev, A. S. Alekseev, V. V. Svetukhin, A. V. Zhukov, A. N. Fomin, R. A. Kuznetsov, et al. "DEVELOPMENT OF TECHNOLOGY FOR THE PRODUCTION OF LU-177: ENGINEERING ASPECTS." Современные наукоемкие технологии (Modern High Technologies), no. 9 2018 (2018): 81–87. http://dx.doi.org/10.17513/snt.37164.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Oosterwijk-Wakka, J. C., W. P. J. Leenders, G. M. Franssen, O. C. Boerman, F. A. Mulders, and E. Oosterwijk. "192 Combination therapy with sunitinib and 177-Lu-girentuximab in RCC." European Urology Supplements 13, no. 1 (April 2014): e192. http://dx.doi.org/10.1016/s1569-9056(14)60190-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Cutler, C. S. "Quality control of research and GMP grade radiometals: Example Lu-177." Nuclear Medicine and Biology 41, no. 7 (August 2014): 637. http://dx.doi.org/10.1016/j.nucmedbio.2014.05.128.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Lakes, A., S. Gauny, D. An, J. Rees, C. Ansoborlo, V. Sisodiya, K. Mcknight, and R. Abergel. "Ac-225 vs Lu-177 radioimmunoconjugates in vitro and in vivo." Nuclear Medicine and Biology 72-73 (July 2019): S15. http://dx.doi.org/10.1016/s0969-8051(19)30230-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Akbar, Muhammad Usman, Tanveer Hussain Bokhari, Muhammad Khalid, Muhammad Razeen Ahmad, Samina Roohi, Saira Hina, Sajid Mehmood, Muhammad Sohaib, and Tania Jabbar. "Radiolabeling, quality control, and biological characterization of 177 Lu-labeled kanamycin." Chemical Biology & Drug Design 90, no. 3 (March 15, 2017): 425–31. http://dx.doi.org/10.1111/cbdd.12960.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Kovan, Bilal, Bayram Demir, Duygu Tuncman, Veli Capali, and Cuneyt Turkmen. "Gamma radiation exposure of accompanying persons due to Lu-177 patients." EPJ Web of Conferences 100 (2015): 03002. http://dx.doi.org/10.1051/epjconf/201510003002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Kim, Keunyoung, and Seong-Jang Kim. "Lu-177-Based Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors." Nuclear Medicine and Molecular Imaging 52, no. 3 (November 20, 2017): 208–15. http://dx.doi.org/10.1007/s13139-017-0505-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Xu, Qin, Shumao Zhang, Yan Zhao, Yue Feng, Lin Liu, Liang Cai, Wei Zhang, et al. "Radiolabeling, quality control, biodistribution, and imaging studies of 177 Lu-ibandronate." Journal of Labelled Compounds and Radiopharmaceuticals 62, no. 1 (November 28, 2018): 43–51. http://dx.doi.org/10.1002/jlcr.3694.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Kang, Keon Wook. "Functional Imaging and Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumor." Korean Journal of Pancreas and Biliary Tract 26, no. 1 (January 31, 2021): 10–14. http://dx.doi.org/10.15279/kpba.2021.26.1.10.

Full text

Abstract:

Somatostatin receptors (SSTR) are overexpressed in various tumors including neuroendocrine tumors. In-111 Octreoscan or Ga-68 DOTATOC positron emission tomography/computed tomography (PET/CT) showed these SSTR expressing tumors in whole body of patients. Ga-68 DOTATOC PET/CT has a better sensitivity and resolution than In-111 Octreoscan with single photon emission computed tomography (SPECT)/CT.. The indications of Ga-68 DOTATOC PET/CT are 1) staging: detect sites of primary and metastasis, 2) re-staging: follow-up of patients with known disease to detect residual, recurrent or progressive disease, 3) prognosis & management decisions: determine SSTR status & select patients with SSTR radionuclide therapy, and 4) monitor the response to therapy. Nuclear medicine treatments for neuroendocrine tumors with radioisotope labeling on the somatostatin receptor targeting peptide (peptide receptor radionuclide therapy, PRRT) were conducted in Europe, Australia, and other countries for over 20 years. Eligible patients to be effective to PRRT using Lu-177 DOTATATE can be pre-screened by confirming the expression of somatostatin receptor on tumors using Octreoscan or Ga-68 DOTATOC PET/CT prior to treatment. This pair of molecular targeted treatment and companion diagnostics, so called molecular theranostics makes PRRT a good example for a precision medicine. A multinational clinical trial with the Lu-177 DOTATATE treatment (Lutathera) showed a significant progression free survival over the control group and Ministry of Food and Drug Safety in Korea approved Lutathera. Some doctors are treating patients who are refractory to Lu-177 using Ac-225, an alpha-emitter therapy in Germany and India. The high therapeutic effect of the alpha emitting radionuclides will lead the future of nuclear medicine therapy.

APA, Harvard, Vancouver, ISO, and other styles

46

Fitschen, Jürgen, Bernd O. Knoop, Rüdiger Behrendt, Wolfram H. Knapp, and Lilli Geworski. "Äußere Strahlenexposition und effektive Halbwertszeit bei Therapie mit Lu-177-Dota-Tate." Zeitschrift für Medizinische Physik 21, no. 4 (December 2011): 266–73. http://dx.doi.org/10.1016/j.zemedi.2011.05.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Das, Tapas, Mohini Guleria, and Sharmila Banerjee. "Formulation of clinical-scale 177 Lu-PSMA-617: From laboratory to clinics." Nuclear Medicine and Biology 43, no. 12 (December 2016): 836. http://dx.doi.org/10.1016/j.nucmedbio.2016.08.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Paganelli, Giovanni, and Ugo De Giorgi. "[ 177 Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet?" Lancet Oncology 19, no. 6 (June 2018): 725–26. http://dx.doi.org/10.1016/s1470-2045(18)30268-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Raharja, Christian, Edward Sun, Judy Gabrys, and Rebecca Wong. "Assessing Dose Administration of Lu-177 DOTATATE Therapy: Quantifying the Residual Dose." Journal of Medical Imaging and Radiation Sciences 49, no. 2 (June 2018): 4–5. http://dx.doi.org/10.1016/j.jmir.2018.04.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Kellett, M. A. "177 Lu: DDEP Evaluation of the decay scheme for an emerging radiopharmaceutical." Applied Radiation and Isotopes 109 (March 2016): 129–32. http://dx.doi.org/10.1016/j.apradiso.2015.11.057.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Lu-177'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles